Nyxoah (NASDAQ:NYXH – Free Report) had its target price boosted by Cantor Fitzgerald from $10.00 to $14.00 in a research note issued to investors on Friday morning, Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.
A number of other equities research analysts have also recently commented on the company. Piper Sandler raised their price objective on Nyxoah from $10.00 to $15.00 and gave the company an overweight rating in a research note on Thursday, February 1st. HC Wainwright reissued a buy rating and issued a $15.00 target price on shares of Nyxoah in a research report on Monday, December 11th. Finally, Stifel Nicolaus decreased their target price on Nyxoah from $14.00 to $10.00 and set a buy rating for the company in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Nyxoah currently has an average rating of Moderate Buy and an average price target of $13.50.
Nyxoah Price Performance
Hedge Funds Weigh In On Nyxoah
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NYXH. Invesco Ltd. purchased a new position in Nyxoah during the first quarter worth about $8,177,000. Sei Investments Co. bought a new stake in shares of Nyxoah in the 2nd quarter valued at about $265,000. Millennium Management LLC bought a new stake in shares of Nyxoah in the 4th quarter valued at about $51,000. ExodusPoint Capital Management LP bought a new position in Nyxoah during the 1st quarter valued at approximately $97,000. Finally, AXA S.A. grew its holdings in shares of Nyxoah by 1.4% during the 1st quarter. AXA S.A. now owns 217,000 shares of the company’s stock worth $1,621,000 after acquiring an additional 3,000 shares during the period.
Nyxoah Company Profile
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
- Five stocks we like better than Nyxoah
- Learn Technical Analysis Skills to Master the Stock Market
- MarketBeat Week in Review – 2/5 – 2/9
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Cloudflare results spark analysts reset: 25% upside ahead
- Stock Market Sectors: What Are They and How Many Are There?
- Beyond Nvidia: The hidden stars with 200% earnings growth
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.